PRIMARY MYELOFIBROSIS
Clinical trials for PRIMARY MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for PRIMARY MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested to fight rare blood cancer
Disease control TerminatedThis study tested whether adding a new drug called parsaclisib to an existing treatment (ruxolitinib) could better control myelofibrosis, a serious bone marrow cancer. It involved 252 adults with intermediate or high-risk disease who had not previously taken similar medications. …
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Halted trial tests new shot for rare bone marrow cancer
Disease control TerminatedThis study tested whether a drug called P1101 could help control myelofibrosis, a rare cancer that scars the bone marrow. It involved 11 patients with early-stage disease who received injections every two weeks. The main goal was to see if the treatment could shrink enlarged sple…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for blood cancer patients: trial tests combo therapy for tough cases
Disease control TerminatedThis study tested whether adding a new drug called parsaclisib to the standard treatment (ruxolitinib) could help people with myelofibrosis, a serious bone marrow cancer, who weren't getting a good enough response from ruxolitinib alone. It involved 177 participants and compared …
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC